Currently, Nyloxin is available as an oral spray in US for joint pain, back pain, neck aches, migraines, headaches and neuralgia and as atopical gel to treat arthritis pain, neck pain, jaoint pain and pain from repetitive stress.
Following the approval, Nutra Pharma is received orders through distributor, Nutritional Alliance, for export to India-based importers.
Nutra Pharma chairman and CEO Rik Deitsch said the India approval is their first regulatory authorization overseas and represents one of the more significant international market opportunities for Nyloxin.